These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32842338)

  • 1. [Progress in the treatment of neuromyelitis optica spectrum disorders related optic neuritis].
    Song HL; Xu QG; Wei SH
    Zhonghua Yan Ke Za Zhi; 2020 Jul; 56(7):539-543. PubMed ID: 32842338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence-based management of optic neuritis.
    Bergeron E; Bouffard MA
    Curr Opin Ophthalmol; 2024 Jan; 35(1):73-82. PubMed ID: 37846574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore.
    Foo R; Yau C; Singhal S; Tow S; Loo JL; Tan K; Milea D
    Asia Pac J Ophthalmol (Phila); 2022 Mar-Apr 01; 11(2):184-195. PubMed ID: 35533337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on neuromyelitis optica spectrum disorder.
    Holroyd KB; Manzano GS; Levy M
    Curr Opin Ophthalmol; 2020 Nov; 31(6):462-468. PubMed ID: 33009077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optic neuritis: current challenges in diagnosis and management.
    Benard-Seguin E; Costello F
    Curr Opin Neurol; 2023 Feb; 36(1):10-18. PubMed ID: 36630210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of plasma exchange for the treatment of optic neuritis in neuromyelitis optica spectrum disorders: A protocol for systematic review and meta-analysis.
    Han M; Chen Y; Nong L; Liu Z; Hao L; Wang Z
    Medicine (Baltimore); 2020 Jul; 99(28):e21067. PubMed ID: 32664124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive review of the advances in neuromyelitis optica spectrum disorder.
    Siriratnam P; Huda S; Butzkueven H; van der Walt A; Jokubaitis V; Monif M
    Autoimmun Rev; 2023 Dec; 22(12):103465. PubMed ID: 37852514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuromyelitis optica spectrum disorders.
    Huda S; Whittam D; Bhojak M; Chamberlain J; Noonan C; Jacob A
    Clin Med (Lond); 2019 Mar; 19(2):169-176. PubMed ID: 30872305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features and visual prognosis of very late-onset neuromyelitis optica spectrum disorder-related optic neuritis.
    Yang Q; Lai C; Meng C; Chang Q; Wei N; Wang J
    Neurol Sci; 2024 May; 45(5):2191-2197. PubMed ID: 37982973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual disability in neuromyelitis optica spectrum disorders: prognostic prediction models.
    Luo W; Kong L; Chen H; Wang X; Du Q; Shi Z; Zhou H
    Front Immunol; 2023; 14():1209323. PubMed ID: 37350969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders.
    Preziosa P; Amato MP; Battistini L; Capobianco M; Centonze D; Cocco E; Conte A; Gasperini C; Gastaldi M; Tortorella C; Filippi M
    J Neurol; 2024 Jul; 271(7):3879-3896. PubMed ID: 38771385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.
    Kleiter I; Gold R
    Neurotherapeutics; 2016 Jan; 13(1):70-83. PubMed ID: 26597098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging concepts in the treatment of optic neuritis: mesenchymal stem cell-derived extracellular vesicles.
    Aneesh A; Liu A; Moss HE; Feinstein D; Ravindran S; Mathew B; Roth S
    Stem Cell Res Ther; 2021 Dec; 12(1):594. PubMed ID: 34863294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromyelitis Optica Spectrum Disorder in Latin America: State-of-the-Art and Current Challenges.
    Carnero Contentti E; Eizaguirre B; López PA; Silva B; Tkachuk VA; Tizio S; Alonso R
    J Integr Neurosci; 2024 Apr; 23(4):74. PubMed ID: 38682226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optic Neuritis Following the BNT162b2 mRNA COVID-19 Vaccine in a Patient with Systemic Lupus Erythematosus Uncovering the Diagnosis of Neuromyelitis Optica Spectrum Disorders.
    Shirah B; Mulla I; Aladdin Y
    Ocul Immunol Inflamm; 2023 Aug; 31(6):1213-1215. PubMed ID: 35849732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromyelitis optica spectrum disorder: Exploring the diverse clinical manifestations and the need for further exploration.
    Noori H; Marsool MDM; Gohil KM; Idrees M; Subash T; Alazzeh Z; Prajjwal P; Jain H; Amir O
    Brain Behav; 2024 Aug; 14(8):e3644. PubMed ID: 39135307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual improvement in a case of neuromyelitis optica spectrum disorder-related optic neuritis after 18 months of treatment with satralizumab: A case report.
    Qiu Y; Shen T; Qiu W; Yang H
    Heliyon; 2024 Aug; 10(15):e35142. PubMed ID: 39157378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of neuromyelitis optica spectrum disorder: revisiting the complement system and other aspects of pathogenesis.
    Ponleitner M; Rommer PS
    Wien Med Wochenschr; 2024 Feb; 174(1-2):4-15. PubMed ID: 36472724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic plasma exchange for neuromyelitis optica attacks: Evidence and challenges from a real-world cohort from Brazil.
    de Almeida GMR; de Araujo RS; Castrillo BB; Silva GD; Fortini I; Gonçalves MRR; Castro LHM; Tatsui NH; Adoni T; Sato DK; Apóstolos-Pereira SL; Callegaro D
    J Neuroimmunol; 2024 Mar; 388():578295. PubMed ID: 38280268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Difficult Diagnosis And Challenging Management Of An Aggressive Case Of Aquaporin 4 Negative Nmosd.
    Khan A; Zahoor W; Zehra T; Ullah Z; Syed NM
    J Ayub Med Coll Abbottabad; 2023; 35(3):515-518. PubMed ID: 38404108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.